MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that it will be featured in an upcoming episode of Innovations with Ed Begley Jr., airing 1st QT 2016 via the Discovery Channel. Dates and show times to be advised.
MMJ PhytoTech Limited (ASX:MMJ) (the "Company") advises that APP Securities Pty Ltd has issued an updated research report which is available on the Company's website
MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that its Swiss-based subsidiary Satipharm generated the Company's first revenues from sales of its game-changing CBD (Cannabidiol) Capsules in the month of August. The Company also announces the official launch of Satipharm.com, where retail customers in the European Union (the "EU") can purchase the Capsules today.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that its subsidiary, PhytoTech Therapeutics, has received official National approval in Israel to commence a Phase I Clinical Study to assess the safety and performance of its proprietary oral capsule formulations.
PhytoTech Medical Limited (ASX:PYL), is pleased to announce that it has completed the acquisition of 100% of the issued capital of MMJ Bioscience Inc. (MMJ). Shareholder approval was received on 29 June 2015 and all regulatory approvals have been satisfied to allow for the completion of the transaction.
PhytoTech Medical Ltd (ASX:PYL) are pleased to provide an investor presentation titled 'From Farm to Pharma - Unlocking the Medical Cannabis Value Chain'; a science-driven, global approach focused on the medicinal potential of Cannabis and its derivatives.
PhytoTech Medical Ltd (ASX:PYL) is pleased to announce that Satipharm AG ("Satipharm"), a 100% controlled entity of MMJ Bioscience Limited ("MMJ"), has signed an agreement with AI FAME GmbH ("AI FAME") to market and distribute its Medical Cannabis products globally.
